glp 1 drugs and ms 2024 Multiple Sclerosis Highlight The Rise of GLP-1 Medications

Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP

However, the evidence gap between these compounds cannot be overstated

Subgroup analyses Subgroup analyses of each GLP-1RA with multiple doses Among the 15 GLP-1RAs, 11 involved multiple doses in the included trials

Furthermore, the SUMMIT trial demonstrated a significant decrease in the hard composite endpoint of cardiovascular death or worsening HF

Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes

Lysosomal acid lipase as a molecular target of the very low carbohydrate ketogenic diet in morbidly obese patients: the potential effects on liver steatosis and cardiovascular risk factors